arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Arcus Biosciences, Inc.

RCUS
$17.69 ▼ -1.61 (-8.32%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
40 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
27
Health
Poor
Bearish
auto_awesome

Analytical Summary

Arcus Biosciences, Inc. faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $2.2B
Dividend Yield —
Revenue Growth -74.4% ↘
Op. Margin -234.1%
ROIC -17.0% ↗
FCF / Share $-0.94 ↗
Trailing P/E —
Price / Book 4.8x
FCF Yield —
Debt / Equity 0.22
info Valuation on last close. End-of-day price, Nov 5, 2026.

40-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$41.00M
↓ -74.4% —
Net Income Profit after all expenses
$-128.00M
↓ -14.3% —
Operating Margin Operating profit as % of sales
-234.1%
↑ +32.2% 1th
FCF / Share Free cash flow per share
$-0.94
↑ +14.2% —
Long-Term Debt Long-term obligations
$101.00M
↑ +1.0% —
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability ↓
1
Returns
15
Financial Health ↑
47
Cash Quality
78

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 11 years · 40 quarters